Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 68 Net Cash per Share is $0.99 as of Dec. 2025, which is 92% below its 10-year median of 12.57. GuruFocus rates HMDCF with a GF Score™ of 68/100 and a GF Value™ of $2.66. The stock has 8 warning signs investors should review. Among 258 Drug Manufacturers companies, HUTCHMED (China) ranks better than 85.66% on this metric.
The historical rank and industry rank for HUTCHMED (China)'s Net Cash per Share or its related term are showing as below:
HMDCF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.32 Med: 12.57 Max: 76
Current: 2.32
During the past 13 years, the highest Price-to-Net-Cash Ratio of HUTCHMED (China) was 76.00. The lowest was 2.32. And the median was 12.57.
HMDCF's Price-to-Net-Cash is ranked better than 85.66% of 258
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs HMDCF: 2.32
HUTCHMED (China) (OTCPK:HMDCF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
HUTCHMED (China) Net Cash per Share Related Terms
HUTCHMED (China) Net Cash per Share Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HMDCF vs ZTS, UTHR, VTRS: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
HUTCHMED (China)'s Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (HMDCF) has a Net Cash per Share of $0.99 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HUTCHMED (China) and its competitors. This is 92% below median its historical median of 12.57. Over the past decade, HUTCHMED (China)'s Net Cash per Share has ranged from 2.32 to 76.00. According to the industry distribution chart, HUTCHMED (China) ranks #37 out of 258 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is HUTCHMED (China)'s Net Cash per Share too high?
HUTCHMED (China)'s current Net Cash per Share of $0.99 is 92% below median its 10-year median of 12.57. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 76.00. The Drug Manufacturers industry median Net Cash per Share is 7.95. HUTCHMED (China)'s value of $0.99 is 87.5% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #37 out of 258 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Net Cash per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #37 out of 258 companies for Net Cash per Share. This places HUTCHMED (China) in the top 14% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 7.95. HUTCHMED (China)'s value of $0.99 is 87.5% below this benchmark. Historically, HUTCHMED (China)'s own Net Cash per Share has ranged from 2.32 to 76.00 over the past decade. While the company's 10-year median is 12.57 vs. the industry median of 7.95, HUTCHMED (China) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 7.95, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Net Cash per Share of $0.99 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Net Cash per Share is $0.99, which is 92% below median its own 10-year median of 12.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Net Cash per Share of $0.99. The stock's GF Value™ is $2.66, compared to a current price of $2.16 — trading 18.8% below its estimated fair value. The current Net Cash per Share is $0.99, which is 92% below median its 10-year median of 12.57 and 87.5% below the Drug Manufacturers industry median of 7.95. HUTCHMED (China)'s overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Net Cash per Share is $0.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 18.8% below its estimated GF Value™ of $2.66.
Key valuation signals for HMDCF:
Net Cash per Share: $0.99 (92% below median its 10-year median of 12.57)
GF Value™: $2.66 vs. price of $2.16 (18.8% below fair value)
Industry Position: 87.5% below the Drug Manufacturers median (#37 of 258)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
68GF Score
Get the complete analysis for HMDCF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
